Bristol Myers Squibb Co. has identified serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular, cerebrovascular, metabolic, inflammatory, neurological and immunological disorders, among others.

Isosterix Inc. has synthesized histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.

Hangzhou Synrx Therapeutics Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of triple-negative breast cancer.

Hanmi Pharmaceutical Co. Ltd. has described son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.

Beyond Therapeutics Co. Ltd. has divulged menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.

Bayer AG has identified α2C-adrenoceptor antagonists reported to be useful for the treatment of dysphagia, snoring, neurodegeneration, neuroinflammation and cardiovascular disorders.

Bristol Myers Squibb Co. has synthesized receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of inflammatory bowel disease, psoriasis, rheumatoid arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), multiple sclerosis, amyotrophic lateral sclerosis, heart failure and Alzheimer’s disease.

Chengdu Chipscreen Pharmaceutical Ltd. has disclosed integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of fibrosis.

Neushen Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, cardiovascular disorders, neurodegeneration and chronic obstructive pulmonary disease.

Negio Therapeutics NV has divulged guanfacine derivatives acting as α2-adrenoceptor agonists reported to be useful for the treatment of cancer.